Despite some recent criticisms of environmental, social and governance (ESG) initiatives and their proponents, demands for ESG information, including by large institutional investors and regulators, are expected to continue. To this end, many smaller public biotech companies appear to be making progress toward addressing the ESG risks and opportunities affecting them and their industry.
Please see full publication below for more information.
